NEW YORK, NY — March 3, 2002 — New findings suggest that mometasone furoate nasal spray is effective and well tolerated for the treatment of daytime cough associated with seasonal allergic rhinitis.
The new data were presented here today at the 58th Annual Meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI) by Dr. Sandra Gawchik, with Asthma and Allergy, in Upland, Pennsylvania.
Her group evaluated the effectiveness of anti-inflammatory nasal corticosteroid, mometasone furoate nasal spray (MFNS), in relieving seasonal allergic rhinitis (SAR)-associated cough and nasal symptoms in 245 patients 12 years of age or older. Patients had SAR symptoms for at least one year, a positive skin test (skin prick or intradermal) to a prevailing seasonal allergen administered at screening within the previous year, moderate nasal symptoms, and a moderate cough. The trial excluded individuals with cough resulting from causes other than SAR.